Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.
Data from the following clinical trials is discussed:
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)
The recent FDA approvals for relapsed refractory HER2+ MBC:
Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)
The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029